Gardasil, Cervarix face FDA next month

Gardasil will have another chance at broader use next month. The FDA's vaccines advisory committee will meet to consider data on use of the human papillomavirus vaccine in boys and young men. In males, HPV can cause genital warts, penile cancer and other rare cancers. And then there's the herd immunity argument: By vaccinating boys and young men, we'd help prevent their passing the virus to girls and women, thereby bringing down overall incidence.

Whether the FDA's expert advisors will think that these benefits outweigh the potential risks of expanding Gardasil use is up for grabs. They weren't thrilled about the idea of expanding Gardasil use to older women--ages 27 to 45--when it came up in January. The committee asked for more data, which is expected in the fourth quarter.

Meanwhile, Gardasil faces a threat at the same committee meeting next month. GlaxoSmithKline's HPV vaccine Cervarix is up for approval then, too. If the committee chooses to recommend this Gardasil rival, Merck will face head-to-head competition for Gardasil in the U.S. for the first time.

- read the FDA meeting agenda

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.